294182-28-8

Upstream product

• 144025-04-7 (2,4-difluorophenyl)magnesium bromide 
• 348-57-2 2,4-difluorobromobenzene 
• 186581-53-3 diazomethane 
• 294182-06-2 2-(5-bromopyridin-2-yl)-1-(2,4-difluorophenyl)-2,2-difluoroethanone 
• 624-28-2 2,5-dibromopyridine 
• 1774-47-6 trimethylsulfoxonium iodide 
• 294181-95-6 2-(5-bromopyridine-2-yl)-2,2-difluoroacetic acid ethyl ester 

Downstream Products

• 1340593-79-4 (6-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)pyridin-3-yl)boronic acid 
• 1340593-96-5 2-((2-(2,4-difluorophenyl)oxiran-2-yl)difluoromethyl)-5-(4-(trifluoromethoxy)phenyl)pyridine 
• 1357018-82-6 C₂₁H₁₂F₇NO 
• 1340593-90-9 C₂₀H₁₂F₅NO 
• 1340593-92-1 C₂₂H₁₄F₇NO₂ 
• 1357018-83-7 C₂₁H₁₂F₄N₂O 
• 1340593-89-6 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-(4-fluorophenyl)pyridin-2-yl)-3-(1H-1,2,4-triazol-1-yl)propan-2-ol 
• 1340593-91-0 2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-1,2,4-triazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol 
• 1340593-95-4 2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-1,2,4-triazol-1-yl)-1-(5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)propan-2-ol 
• 1340593-97-6 2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-1,2,3-triazol-1-yl)-1-(5-(4-(trifluoromethoxy)phenyl)pyridin-2-yl)propan-2-ol 
• 1340593-61-4 4-(6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)benzonitrile 
• 1340593-62-5 2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)propan-2-ol 
• 1340593-80-7 C₂₃H₁₄F₉NO₂ 
• 1340593-69-2 2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(trifluoromethoxy)phenyl)-pyridin-2-yl)propan-2-ol 

Relevant academic research and scientific papers

Fungal lanosterol 14α-demethylase (CYP51) inhibitor Treatment of recurrent vulvovaginal candidiasis Treatment of onychomycosis

Developing a rationally designed, more selective azole antifungal agent that specifically targets the fungal CYP51 over the host CYP51 is a severe unmet need considering a massive shortfall in novel antifungal agents. In this context, oteseconazole (VT-1161) represents a very exciting new development targeting serious fungal infections caused by a wide variety of fungal pathogens including multidrug-resistant Candida responsible for recurrent vulvovaginal candidiasis. This monograph details the various in vitro and in vivo properties exhibited by oteseconazole as well as its current status in clinical trials.

Deuterated azole alcohol compound, preparation method and uses thereof

The present invention discloses a deuterated azole alcohol compound represented by a formula (I), and a pharmaceutically acceptable salt thereof, a preparation method and uses thereof, and a prodrug.According to the present invention, the deuterated azole alcohol compound has good antifungal activity and good metabolic stability, and can be used for preparing antifungal drugs. The formula (I) isdefined in the specification.

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

ANTIFUNGAL COMPOUND PROCESS

The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.

ANTIFUNGAL COMPOUND PROCESS

The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.

Design and optimization of highly-selective fungal CYP51 inhibitors

While the orally-active azoles such as voriconazole and itraconazole are effective antifungal agents, they potently inhibit a broad range of off-target human cytochrome P450 enzymes (CYPs) leading to various safety issues (e.g., drug-drug interactions, li

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

METALLOENZYME INHIBITOR COMPOUNDS

The present disclosure describes compounds having agricultural fungicidal activity.

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.